OMER•benzinga•
Omeros Announces Results For Narsoplimab Expanded Access Program In TA-TMA; Results Demonstrate Marked Survival Superiority Of Narsoplimab-Treated EAP Patients, In Stand-Alone And Combined Analyses With Narsoplimab Pivotal Trial Patients, Over External Co
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 20, 2025 by benzinga